彩盈彩票

NEWS more +

  • Zai Lab Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Updates

  • Zai Lab Announces Acceptance of sNDA Submission of ZEJULA (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China by the NMPA

  • Zai Lab Announces Acceptance of NDA Submission of Omadacycline in China by the NMPA

友情链接:pk10注册平台  开心快乐8  时时彩官网  幸运飞艇官网平台  111彩票平台  V8彩票官网  pc28  乐米彩票平台  时时彩官网  极速飞艇登录网站